Navigation Links
Michael J. Fox Foundation Awards $710,000 to Understanding of Parkinson's Disease Subtypes

NEW YORK, The Michael J. Fox Foundation for Parkinson's Research announced $710,000 in total funding to seven research teams for projects leveraging existing data and patient populations to initially characterize Parkinson's disease subtypes -- distinct forms of the disease that may differ in onset, progression and response to treatment.

"One of the most frustrating aspects of Parkinson's disease -- for patients, researchers and clinicians alike -- is the significant variability in how the disease manifests itself from patient to patient," said Sarah Orsay, chief executive officer of the Foundation.

"The retrospective studies funded under PD Subtypes aim to analyze data already gathered on different forms of the disease. This analysis could yield valuable information with potential to improve clinicians' ability to treat patients with existing therapies. It could also advance development of new treatments and enable better design of future clinical trials."

Applicants under PD Subtypes were required to propose research that would make use of existing data from well-characterized populations of Parkinson's patients. Several researchers will mine specific databases established by their own institutions for various purposes.

Others will work from some of the most important clinical research populations in the Parkinson's field, including the DATATOP (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism) study population of 800 early-stage Parkinson's patients and the PRECEPT (Parkinson Research Examination of CEP-1347 Trial) population of 800 patients.

Nick Holford, MBChB, FRACP, of the University of Auckland will use a unique statistical approach to test the value of early measures of disease status in predicting the probable time to clinical events such as dementia, falls and depression.

Connie Marras, MD, PhD FRCP(C), of Toronto Western Hospital will focus on determining pr edictive factors for reaching a common neuroprotective clinical trial endpoint -- time to disability requiring dopamine replacement therapy. She will use PRECEPT data to validate an earlier study she conducted in the DATATOP population. This previous study examined factors including smoking, disease duration, and tremor as an initial symptom.

Stephen Van Den Eeden, PhD, of the Kaiser Foundation Research Institute will assess predictive factors -- including age at diagnosis, gender, family history and race -- that may bear on mortality in Parkinson's disease.

Other funded studies will examine aspects of PD including whether it is possible to identify PD subgroups based on areas of disability (cognitive, balance, motor function) seen at the last available clinical visit; and factors (such as mood analysis, sleep, cognitive function and pain) that may contribute to the identification of novel PD subtypes.

Leadership funding for PD Subtypes was provided by the Kinetics Foundation of Los Altos, California. "We look forward to a continuing partnership between The Michael J. Fox Foundation for Parkinson's Research and the Kinetics Foundation as we work to improve PD diagnosis and treatment by characterizing disease subtypes," said Ken Kubota, Kinetics' director of programs.


'"/>




Related medicine news :

1. Gest Says Will Reveal Damning Secrets On Michael Jackson
2. Where is Our Soul, Asks Michael Moore
3. Ask Right Questions and Save Country from Further Healthcare Crisis: Michael Moore
4. Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program
5. Kalam To Lay Foundation Of Vellore Research Center
6. Nippon Foundation To Help Leprosy Patients
7. Parents Launch SV40 Cancer Foundation In Memory of Son
8. Cancer Aid And Research Foundation: Offering Endless Hope To Cancer Patients
9. PM Launches Healthcare Foundation For India
10. Prime Minister Manmohan Singh, Flags Off Public Health Foundation of India
11. Gates Foundation to donate USD 104 million to TB Alliance
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2017)... ... ... Month and the focus is on prostate cancer. Second only to skin cancer, prostate ... common cause of cancer related death today; lung cancer remains in the number one spot. ... during his lifetime. Those at highest risk are men who have a family ...
(Date:6/24/2017)... ... ... Doorknobs are for convenience, deadbolts are for security. , There are many ... an alarm system installed. But unless there is a working deadbolt lock that is ... Premier Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders use ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and antioxidants derived ... loss in these patients. , But how often do ophthalmologists and optometrists in Sweden ... at risk of or with early symptoms of AMD? A study published recently ...
(Date:6/23/2017)... ... ... Goodcents Deli Fresh Subs today announced the opening of a new restaurant ... Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by long-time ... in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such a ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent ... is MD Now’s 28th facility overall and marks the urgent care center's eighth location ... mile North of The Falls shopping mall. The new clinic offers a wide array ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... -- Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), ... selection of stem cells, today provided a corporate update ... March 31 st , 2017. "We ... quarter of 2017," said Dr. Shai Yarkoni, Chief Executive ... of the first blood cancer patient in the recently ...
Breaking Medicine Technology: